$13.31 -$0.13 (-1.0%)

03:55 PM EDT on 10/18/19

Olympus Corp (ADR) (NASDAQOTH:OCPNY)

CAPS Rating: No stars

Current Price $13.31 Mkt Cap $1,865.4B
Open $13.33 P/E Ratio 59.21
Prev. Close $13.44 Div. (Yield) $0.00 (0.0%)
Daily Range $13.31 - $13.33 Volume 408
52-Wk Range $2.89 - $13.79 Avg. Daily Vol. 4,213

Caps

How do you think NASDAQOTH:OCPNY will perform against the market?

Add Stock to CAPS Watchlist

All Players

5 Outperform
2 Underperform
 

All-Star Players

0 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQOTH:OCPNY Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

Tak3natheFlood (99.32)
Submitted May 19, 2009

Overpriced based on book as they are losing money at the same time in this environment as consumers and medical professionals pull back. Any revenue gains in these areas will be offset by a loss of pricing power due to the lowered willingness to buy… More

NASDAQOTH:OCPNY VS S&P 500 (SPY)

Fools bullish on NASDAQOTH:OCPNY are also bullish on:

Fools bearish on NASDAQOTH:OCPNY are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about OCPNY.

Recs

0
Member Avatar dnelyo (< 20) Submitted: 11/25/2011 11:25:46 AM : Underperform Start Price: $3.39 NASDAQ OTHER:OCPNY Score: -138.48

delisting possible

Recs

0
Member Avatar catfishalex (36.77) Submitted: 5/6/2010 7:10:33 PM : Outperform Start Price: $7.58 NASDAQ OTHER:OCPNY Score: -74.10

hate the crappy digital cameras, love the simoidoscopes. recent studies have shown that flexible sigmoidoscopy can greatly reduce colon cancer death rates and is an easier procedure to do than a colonoscopy and will be used to see if a colonoscopy is necessary. I expect sigmoidoscope usage to skyrocket.

Recs

0
Member Avatar didIpickthat (< 20) Submitted: 1/30/2008 9:05:59 PM : Outperform Start Price: $8.36 NASDAQ OTHER:OCPNY Score: -71.21

The next wave of advanced endoscopic surgery is currently being developed and in minimally invasive surgery. Olympus will be buying out ACMI to get a hold of 2 patents that are needed for this break through surgery. Currently, studies are underway in Asia and Europe with promising results. Stayed tuned for the next big break-through in surgical procedures. It will mean big gains for this company.

Leaderboard

Find the members with the highest scoring picks in OCPNY.

Score Leader

senkihazi

senkihazi (99.96) Score: +68.30

The Score Leader is the player with the highest score across all their picks in OCPNY.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
ztrategist 27.67 6/6/2008 Underperform 1Y $8.13 +63.76% +124.08% +60.31 0 Comment
alfretaddei 67.68 1/30/2013 Outperform 3Y $5.51 +141.66% +97.97% +43.69 0 Comment
morgand27 < 20 3/13/2008 Outperform 3Y $7.17 +85.57% +134.38% -48.81 0 Comment
25000THEVA < 20 3/23/2007 Outperform NS $8.64 +54.10% +120.03% -65.94 0 Comment
didIpickthat < 20 2/1/2008 Outperform 5Y $8.36 +59.16% +130.38% -71.21 1 Comment
catfishalex 36.77 4/28/2010 Outperform 5Y $7.58 +75.71% +149.81% -74.10 1 Comment
dnelyo < 20 11/25/2011 Underperform 3Y $3.39 +292.63% +154.15% -138.48 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for OCPNY.